Friday, November 22, 2013

08:30-10:00
DOES THE FRAX INDEX REALLY REFLECT SOCIETY, AND THEREFORE, USEFUL IN THE TREATMENT OF OSTEOPOROSIS (OP)?
Capsule
To assess the ability of the WHO fracture risk assessment tool (FRAX®) to predict the observed incident fractures in different countries
Chairpersons S. Palacios, Spain
R. Meier, Switzerland
The Icelandic experience
B. Gudbjornsson, Iceland
The Spanish experience
N. Guanabens, Spain
The UK experience
M. Rees, UK
"Under 34" competition winner:
A synergistic interaction of 17-β estradiol and specific cb-2 antagonist on proliferation activity in primary human osteoblasts – preliminary results
M. Hojnik, Slovenia
Objectives To acquire knowledge of the following:
  • FRAX tool and fracture risk factors
  • How to estimate the risk of fracture
  • To know the discriminative ability of FRAX tool for fracture risk in different countries
10:30-12:00
NEW INSIGHTS IN PATHOGENESIS OF RHEUMATOID ARTHRITIS (RA)
Capsule
The role played by different subsets of immune cells and cytokines are crucial in developing rheumatoid arthritis and are also important in the progression of the disease. This will eventually lead to the development of new targets for treating the disease
Chairpersons C. Evans, USA
C. Miceli, France
Debate: What is the main actor of RA ?
B cells and RA: P. Youinou, France
T cells and RA: G.F. Ferraccioli, Italy
Debate
Immunopathogenic Process in RA
A. Ioan-Facsinay, Netherlands
Adipokines and RA and chondrocytes pathophysiology
O. Gualillo, Spain
Objectives To acquire knowledge of the following:
  •  To assess the physiopathogenic process involved in early and established RA
  • Identification of possible new targets based on different pathways involved in RA
  • Relationship between Ly B and T, and also the role of adipokines (Leptin, Visfatin, etc.) in RA
12:50-14:20
BISPHOSPHONATES: HOW LONG IS LONG ENOUGH? THE CONCEPT OF A DRUG HOLIDAY
Capsule
Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy
Chairpersons J.J. Scali, Argentina
G.F. Ferraccioli, Italy
Switching to other drugs or drug holiday?
R. Meier, Switzerland
The burden of bisphosphonate-associated atypical fractures
H. Weinans, Netherlands
Bisphosphonates in women vs. in men: Are they the same?
M. Cohen-Solal, France
Objectives To acquire knowledge of the following:
  • To assess the benefits and risks of long-term bisphosphonates
  • Identification of possible candidates and monitoring during a bisphosphonate drug holiday
  • Relation betwen bisphosphonates and atypical fractures
14:40-16:10
THE FUTURE OF OSTEOPOROSIS TREATMENT
Endorsed and organized by the European Menopause and Andropause Society (EMAS)
Capsule
Recent insights into bone biology, have led to a better understanding of bone cell functions and crosstalk between osteoblasts, osteoclasts, and osteocytes at the molecular level.  The armamentarium against osteoporotic fractures will likely be enriched by, new bone anabolic substances, new inhibitors of bone resorption, and new therapeutic strategies
Chairpersons S. Palacios, Spain
M. Rees, UK
Debate: Should sequential treatment for osteoporosis be anabolic followed by anti-resorptiove therapy?
Yes: P. Selby, USA
No: J.C. Gallagher, USA
Discussion
New bone anabolic substances
P. Orcel, France
New inhibitors of bone resorption
J.J.Scali, Argentina
Objectives To acquire knowledge of the following:
  • New bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1
  • PTH and PTHrp
  • New inhibitors of bone resorption such as cathepsin K inhibitors
  • New therapeutic strategies
16:30-18:00
FROM EARLY TO LATE POST MENOPAUSAL OSTEOPOROSIS (OP)
Capsule
The usual patients with low bone mineral density and fracture risk that are seen by gynecologists are often younger than 70 years, while research on drugs is undertaken on women over this age
Chairpersons Z. Ben-Rafael, Israel
S. Palacios, Spain
Debate: Should we treat women with low bone mineral density who are younger than 70 years, and how?
Proposition: Evidence for the effectiveness of drugs at this age is lacking and treatment is not cost-effective
M. Cohen-Solal, France
Opposition: There is enough experience to manage these patients, but therapy should be individualized
J.C. Gallagher, USA
Discussion
Recommendations on the management of fragility risk fracture in women that are younger than 70 Years
S. Palacios, Spain
Objectives To acquire knowledge of the following:
  • Risk factors and prevalence of osteoporotic fractures in women over 70 years
  • Older and newer therapies to prevent fracture
  • Evidence based intervention strategy for postmenopausal OP
  • What role do biomarkers play in patient selection of the optimal intervention? Do they benefit equally from the same intervention?
  • Does the same treatment fit all? Is there an optimal intervention for a given patient?
08:30-10:00
NEW THERAPEUTIC DIRECTIONS IN OSTEOARTHRITIS (OA)
Partially supported by an unrestricted grant from IBSA Institut Biochimique SA
Capsule
There is no cure for OA. Current treatments have a moderate effect on pain and some of them improve joint function, and show a partial structure-modifying effect on the natural course of the disease. Some innovative approaches are under investigation including cell or genetic therapy. Recently, anti-resorptive drugs, currently used in the treatment of osteoporosis, have been proposed as disease modifying drugs. What is the clinical evidence that sustains this innovative approach? This session aims to review the recent advances in treatment of OA
Chairpersons P. Dieppe, UK
D. Serteyn, Belgium
A modern approach to an old disease: Glycosaminoglycans (GAGs) therapy in OA 
Y. Henrotin, Belgium
Gene therapy in OA
C. Evans, USA
Knee OA: Should we give antiresorptive drugs to OA patients?
G. Herrero-Beaumont, Spain
Objectives Upon completion of this session, the audience will have learned about the clinical efficacy of new therapies, mechanisms of action, adverse effects, and recent and future developments
10:30-12:00
INTEGRATION OF HERBAL MEDICINE IN JOINT PAIN MANAGEMENT: UTOPIA OR REALITY?
Supported by an unrestricted grant from Tilman S.A.
Capsule
Botanical extracts and herbal medicines are increasingly marketed and consumed for complementary treatment of joint complaints. However, it is claimed that so far most of the evidence for the anti-inflammatory effects of these products comes from in vitro and in vivo studies. Recently, new clinical trials confirm the benefits of some herbals for these conditions
Chairpersons Y. Henrotin, Belgium
J. Monfort, Spain
Debate: Are botanical extracts and herbal medicines promising oral treatments for rheumatic diseases and musculoskeletal complaints?
Yes: A. Mobasheri, UK
No: S. Toegel, Austria
Discussion
Management of adverse effects in OA treatement
H.K. Biesalski, Germany
Objective To show the evidence for and against the use of herbal medicines for joints and mobility problems
12:50-14:20
PAIN AND PHYSICAL ACTIVITY: FRIEND OR FOE?
Capsule
Exercise is an effective treatment for various chronic pain disorders, including fibromyalgia, chronic neck pain, osteoarthritis, rheumatoid arthritis and chronic low back pain. Although the clinical benefits of exercise therapy in these populations are well established, it is currently unclear whether exercise has positive effects on the process involved in chronic pain (e.g. central pain modulation). Further, it is unclear if exercise is effective in all patients according the origin of the pain neuropathic, nociceptive or inflammation. The question remains whether exercise is recommended for all phenotype patients suffering from pain
Chairpersons L. Danneels, Belgium
M. Vanderthommen, Belgium
Debate: Do we recommend physical activity in patients suffering from pain?
Yes: S. Perrot, France
No: M. Meeus, Belgium
Discussion
Recommendations for evaluating muscle performance in clinical trials
F. Struyf, Belgium
Objectives To acquire knowledge of the following:
  • The impact of physical activity on pain
  • The type of physical activity to relief pain
  • The mechanisms of action of physical activity on pain
14:40-16:10
WHAT IS THE REAL RISK FACTOR FOR OA: TO BE A WOMAN OR TO DEVELOP AN ESTROGEN DEFICIENCY? 
Capsule
Women have a higher risk for developing OA than men. This relationship could be associated to gender-related mechanical joint abnormalities or to changes induced by estrogen deficiency around the menopause that conditionate a kind of pre-osteoarthritis joint
Chairpersons G. Herrero-Beaumont, Spain
Is there an osteroporosis phenotype in OA?
S.M.A. Bierma-Zeinstra, Netherlands
Could estrogen or SERM therapy prevent OA progression?
J.A. Roman-Blas, Peru
The effect of estrogens in chondrocytes biology
R. Largo, Spain 
Round Table Discussion
S.M.A. Bierma-Zeinstra, Netherlands
J.A. Roman-Blas, Peru
R. Largo, Spain
Questions to the panel:
  1. What is the role of estrogens in cartilage metabolism?
  2. Could sex hormone deficiency produce deleterious effect on OA progression?
  3. What is the influence of estrogen hormone replacement in OA outcomes?
  4. Could we consider a deficiency estrogen subgroup in primary OA?
Objective To better understand the relationship among female sex hormones and OA
16:30-18:00
EXERCISE AND ORTHOSES AS TREATMENT OF OA: CAN WE EXPECT A STRUCTURAL EFFECT?
Capsule
Most research on exercise and OA relate to the knee and data cannot necessarily be extrapolated to OA at other sites. Exercise interventions may have different responses depending on the OA site, and the personal, social and cultural context of the patient, but little is known about this
Chairpersons B. Gudbjornsson, Iceland
M. Francaux, Belgium
Can we slow down OA progression with Orthoses?
I. Baert, Belgium
Exercise in OA: What about the hips and hands?
M. Henriksen, Denmark
Increasing the effect of exercise: The importance of context?
M. Hurley, UK
Experts’ opinion on
  1. The role of exercise in non-knee OA
  2. Potential ways to enhance the clinical effects of exercise
"Under 34" competition winner:
Development and validation of a questionnaire assessing volitional competencies to enhance the performance of physical activities in chronic low back pain patients
C. Mathy, Belgium
Objectives Upon completion of this session, the audience will have learned:
  • The role of exercise in treatment of hip and hand OA
  • The importance of contextual factors for the success of OA treatments
  • Hall C
16:30-18:00
APPLYING OMICS TECHNIQUES TO DISCOVER NEW OA BIOMARKERS
This session is endorsed and organized by the D-BOARD F7 consortium for new OA biomarkers discovery
Chairpersons Y. Henrotin, Belgium
A. Mobasheri, UK
Introduction
A. Mobasheri, UK
Chopping off chondrocyte proteome
M. Dvir-Ginzberg, UK
Membranome: source of new OA biomarkers
R. Barrett-Jolley, UK
From “OMICS” to patients: a steep path
P. Douette, Belgium
Bioinformatic to help biomarker discovery
J. Bacardit,UK
Concluding Remarks
Y. Henrotin, Belgium
 

Reduced Registration
Deadline
November 18, 2013
more

 

Keep me updated

KeepMeUpdated2